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The implementation of adjuvant therapy, hormonal therapy, and 
chemotherapy has made a major impact on disease-free survival 
and overall survival in premenopausal and postmenopausal women 
with  early-stage  breast  cancer  (1).  Unfortunately,  many  breast 
cancer patients who are diagnosed and treated properly will suffer 
from recurrence and ultimately die of this disease. Since the intro-
duction  of  anthracycline-based  regimens  for  the  treatment  of 
breast cancer and the demonstration of their superiority to other 
combination  chemotherapy  (1),  a  variety  of  approaches  have 
evolved regarding adjuvant polychemotherapy, including the addi-
tion of novel drugs such as taxanes and targeted agents and the 
establishment of dose-intensive (2) and dose-dense chemotherapy 
regimens (3,4) that were based on mathematical models of human 
breast cancer growth (5).
Administration  of  dose-dense  chemotherapy  became  possible 
with  the  introduction  of  granulocyte  colony-stimulating  factor, 
which allowed the chemotherapy courses to be condensed without 
causing unacceptable toxicity. A dose-dense chemotherapy approach 
using concurrent doxorubicin and cyclophosphamide followed by 
paclitaxel was assessed in the pivotal Cancer and Leukemia Group B 
9741 trial, a phase III prospective randomized trial of adjuvant treat-
ment of women with node-positive early-stage breast cancer (6). 
This trial showed a statistically significant improvement in disease-
free survival and overall survival for the dose-dense chemotherapy 
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arm and has become the cornerstone for the current therapeutic 
treatment of early-stage breast cancer in many centers.
The  Italian  Gruppo  Oncologico  Nord  Ovest-Mammella 
InterGruppo  trial used a similar approach to test a non-taxane–
based  regimen  (7).  Although  the  point  estimates  for  event-free 
survival and overall survival favored the dose-dense regimen, they 
were not statistically significant (7). A third trial in the neoadjuvant 
setting failed to show statistically significant improvement in path-
ological response rates, disease-free survival, or overall survival for 
the dose-dense regimen (8). Several other randomized trials have 
examined the concept of dose-dense chemotherapy (9–18); how-
ever, these studies are difficult to interpret because the treatment 
groups differed in terms of dose density, drug regimens, number 
of cycles, and the application of sequential strategies.
Given this paucity of data, we performed a systematic review 
and meta-analysis of the evidence from randomized trials for the 
efficacy and toxicity of the dose-dense chemotherapy approach in 
the treatment of early-stage and locally advanced breast cancer.
Methods
Search Strategy
Relevant randomized clinical trials were identified by searching 
the  most  recent  update  of  The  Cochrane  Central  Register  of 
Controlled Trials (January 2010), The Cochrane Library (January 
2010 issue), and LILACS (Latin American and Caribbean Health 
Sciences) and MEDLINE databases (January 1, 1966, to January 
1, 2010). The terms “adjuvant,” “neoadjuvant,” and “dose-dense 
chemotherapy” (and similar terms) and “breast cancer” and similar 
terms  were  cross-searched  by  using  the  following  search  algo-
rithm:  ((dose-dense  chemotherapy  OR  dense  OR  acceler*  OR 
weekly  OR  bi-weekly  OR  biweekly)  AND  (Breast  neoplasm 
MeSH OR ((breast OR mammary OR mamario OR seno) AND 
(carcinoma OR malignan* OR neoplasm OR tumor)))) AND (ran-
domized controlled trial [pt]OR controlled clinical trial [pt]OR 
randomized controlled trial [mh]OR double-blind method [mh] 
OR single-blind method [mh] OR clinical trial [pt] OR clinical 
trials [mh] OR (“clinical trial”) [tw] OR singl* [tw] OR doubl* [tw] 
OR trebl* [tw] OR tripl* [tw] AND (mask* [tw] OR blind* [tw]))) 
OR (placebos [mh] OR placebo* [tw] or random* [tw] PR research 
design  [mh:noexp]  OR  comparative  study  [mh]  OR  evaluation 
studies [mh] OR follow up studies [mh] OR prospective studies 
[mh] OR control* [tw] OR prospective* [tw] OR volunteer* [tw] 
NOT (animals [mh] NOT humans [mh]). We also searched for 
relevant  abstracts  in  the  annual  conference  proceedings  up  to 
December 2009 for the American Society of Clinical Oncology, 
European  Society  for  Medical  Oncology,  and  the  San  Antonio 
Breast  Cancer  Symposium.  References  of  selected  articles  were 
scanned for any other relevant trials, and the original trialists were 
contacted about possible unpublished trials.
Selection Criteria
We included in the systematic review all randomized controlled 
trials that compared a dose-dense chemotherapy protocol with a 
standard schedule of chemotherapy in the neoadjuvant or adjuvant 
setting in adult women older than 18 years with breast cancer. 
Trials were included regardless of publication status and language. 
Two trials in a foreign language were assessed by a native speaker 
(neither was included in the meta-analysis). We defined two types 
of trials: Trials that evaluated similar doses of agents in both treat-
ment arms but with condensed schedule in one arm, which we 
designated conserved dose-dense chemotherapy trials, and trials 
that compared a condensed schedule with a standard one but used 
different agents or doses in the two arms were designated modified 
dose-dense chemotherapy trials. Trials in which overall survival 
was the primary outcome measure but was not reported were in-
cluded if all other inclusion criteria were met. Authors of these 
trials were contacted and asked to provide data for the primary 
outcome measure if those data have been collected.
We excluded trials that assessed dose-dense chemotherapy in 
malignancies other than breast cancer or that evaluated dose-dense 
chemotherapy  combined  with  radiotherapy,  trials  in  which  the 
definition of dose-dense chemotherapy differed from the original 
definition (4), trials that included high-dose chemotherapy arms 
with  peripheral  stem  cell  support,  and  randomized  controlled 
phase II trials that evaluated toxicity only.
Two authors (LB and IBA) independently inspected each refer-
ence title identified by the search and applied the inclusion criteria. 
For possibly relevant articles and in cases of disagreement between 
the two reviewers, the full article was obtained and inspected inde-
pendently by the two reviewers.
Data Extraction and Quality Assessment
Trials that fulfilled the systematic review inclusion criteria were 
assessed for methodological quality by two authors (LB and IBA). 







trials  that  compared  dose-dense  chemotherapy  with  a  standard 















The  small  number  of  included  trials  makes  the  outcomes  more 
likely to have been influenced by a potential publication bias.
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sample size, exclusions after randomization, and the length of 
follow-up  were  recorded  as  is  considered  acceptable  for 
Cochrane  reviews  (19).  The  same  two  authors  independently 
extracted the data from publications of included trials. The data 
extraction  was  discussed,  decisions  were  documented,  and,  if 
necessary, the authors of the trials were contacted for clarifica-
tion. Authors of included trials were contacted for all data rele-
vant to the primary and secondary outcomes of this study and 
quality variables.
Outcome Measures
The primary outcome was overall survival, which was defined as 
time  from  randomization  to  death.  Secondary  outcomes  were   
disease-free survival (defined as the time from randomization to 
earliest occurrence of relapse or death from any cause), event-free 
survival (defined as the length of time from the end of treatment 
to the earliest occurrence of a severe side effect of treatment, cancer 
recurrence or progression, or death from treatment side effects or 
from the cancer itself) (www.nature.com/nrc/journal/v3/n7/glossary 
/nrc1125_glossary.html),  and  toxicity  (defined  as  grade  3  or  4 
hematological  and  nonhematological  adverse  events).  For  the 
analysis of toxicity, we calculated the mean number of events per 
chemotherapy cycle by summing all events reported and dividing 
by the number of cycles delivered in each trial.
Possibly relevant randomized controlled trials (n = 302)
Randomized controlled trials 
excluded (n = 264)
Did not evaluate dose dense 
schedule; reviews or were not 
randomized controlled trials
Randomized controlled trials 
included for more detailed 
analysis (n = 38)
Randomized controlled trials 
selected (n = 10)
Randomized controlled trials 
selected for modified dose dense 
chemotherapy analysis (n = 7). 
The MA 21 trial was included for 
RFS analysis.
Randomized controlled trials 
selected for conserved dose- 
dense chemotherapy 
analysis (n = 3)
Randomized controlled trials 
excluded after analysis (n = 29)
Double publication, metastatic 
breast cancer treatment setting, 
phase II trials assessing toxicity, 
two dose-dense arms without 
conventional chemotherapy arm, 
high-dose chemotherapy arm, 
lack of outcomes report including 
the PREPARE trial, which 
reported only pCR outcomes.
Base Data research
Medline, PubMed (n = 4323)
Cochrane (n = 489)
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Statistical Analysis
Hazard ratios (HRs) and variances for time to event outcomes were 
estimated as described by Parmar et al. (20) and pooled according 
to the inverse of variance method with the use of Review Manager 
software (version 4.2 for Windows; The Cochrane Collaboration, 
Oxford, UK). A hazard ratio less than 1 favored dose-dense che-
motherapy. Pooled relative risks (RRs) and 95% confidence inter-
vals  (CIs)  for  dichotomous  data  were  estimated  using  the 
Mantel–Haenszel method (21). We assessed heterogeneity of the 
trials’ results by inspecting graphical presentations and by calcu-
lating a x2 test of heterogeneity and the I2 statistic of inconsistency. 
We  also  report  the  Z  statistic  for  the  overall  effect  (Review 
Manager). Statistically significant heterogeneity was defined as a x2 
P value less than .1 or an I2 statistic greater than 50% (www.nature.
com/nrc/journal/v3/n7/glossary/nrc1125_glossary.html). We used 
a  fixed-effect model to pool relative risks for toxicity except in 
the event of statistically significant heterogeneity, in which case a 
random-effects model was used (ie, the inverse of variance method 
and the DerSimonian and Laird method) (17).
Subgroup analyses were performed to assess potential contribu-
tions to the main outcomes. A funnel plot estimating the precision 
of trials (plots of logarithm of the hazard ratio for efficacy against 
the sample size) was examined for asymmetry to estimate publica-
tion bias. Publication bias was also estimated by the formal Begg–
Mazumdar rank correlation test and the Egger test (18,22).
Sensitivity analyses were performed to assess the robustness of 
the  findings  to  different  aspects  of  the  trials  methodology,  in-
cluding allocation concealment (adequate or unclear), exclusions 
after randomization (reported or not reported), sample size (≤100 
vs >100 patients; cutoff was adopted from routine studies in which 
fewer than 100 patients is considered a “small” study), and length 
of follow-up. All statistical tests were two-sided. P values less than 
0.5 were considered statistically significant.
Results
We identified 4869 potentially relevant articles in the primary lit-
erature search (Figure 1), of which 11 were randomized phase III 
trials that met the inclusion criteria and were divided into two 
groups based on the trial methodology. The first group—the con-
served  dose-dense  chemotherapy  trials—included  three  trials 
(Table 1), and the second group—the modified dose-dense chemo-
therapy  trials—included  seven  trials  (Table  2).  The  PREPARE 
trial (24) was included in the systematic review but not in the meta-
analysis because no survival outcomes were provided. Chemotherapy 
protocols of the included trials are listed in Table 3.
Meta-analysis of Conserved Dose-Dense Chemotherapy 
Trials
A total of 3337 patients were randomly assigned in the three trials 
that  we  classified  as  conserved  dose-dense  chemotherapy  trials 
(6–8). In a meta-analysis of these three trials, patients in the dose-
dense chemotherapy arms had better overall survival than patients 
in the conventional chemotherapy arms (HR of death = 0.84; 95% 
CI = 0.72 to 0.98, P = .03), and there was no heterogeneity among 
these trials with respect to overall survival (I
2 = 0%) (Figure 2). 
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Figure 2. Forest plot of hazard ratios (HRs) comparing overall survival 







timated  overall  effect  based  on  the  meta-analysis  fixed  effect  of  all 
trials. 
disease-free survival (HR of relapse or death = 0.83; 95% CI = 0.73 
to 0.94, P = .005), with no heterogeneity (I
2 = 0%) (Figure 3). In a 
sensitivity analysis based on estrogen and progesterone receptor 
status using data from the two trials that examined disease-free 
survival (6,7), dose-dense chemotherapy had a statistically signifi-
cant benefit with respect to disease-free survival only in receptor-
negative patients (HR of relapse or death = 0.71; 95% CI = 0.56 to 
0.89; I








95%  confidence  interval  (CI).  The  diamonds  represents  the  estimated 
overall effect based on the meta-analysis fixed effect of all trials. ‡EC then 
T (dose-dense arm) vs AC then T. §EC then T (dose-dense arm) vs CEF.jnci.oxfordjournals.org    JNCI | Articles 1851
Meta-analysis of Modified Dose-Dense Chemotherapy 
Trials
A total of 8652 patients were randomly assigned to seven trials 
classified as modified dose-dense chemotherapy trials (11–16,23) 
that evaluated efficacy and toxicity of dose-dense chemotherapy in 
the adjuvant and neoadjuvant settings. In a meta-analysis of six of 
these trials (11–16), patients in the dose-dense chemotherapy arms 
had statistically significantly better overall survival than patients   
in the conventional chemotherapy arms (HR of death = 0.85; 95%   
CI = 0.75 to 0.96); heterogeneity in overall survival among the 
trials was low (I
2 = 15.5%) (Figure 2). Dose-dense chemotherapy 
had a similar benefit with respect to disease-free survival in these 
six trials (HR of relapse or death = 0.81; 95% CI = 0.73 to 0.88) 
although the heterogeneity was high (I
2 = 53.9%) (Figure 3). An 
analysis by receptor status was not performed because of the lack 
of  these  data.  In  the  MA21  trial  (23),  relapse-free  survival  did   
not differ between the treatment arms in the estrogen receptor–
positive population.
Meta-analysis of Efficacy for All Dose-Dense 
Chemotherapy Trials
A  meta-analysis  of  all  dose-dense  chemotherapy  trials  (6–8,11–
16,23)  revealed  that  patients  who  received  dose-dense  chemo-
therapy had statistically significantly better overall survival (HR of 
death = 0.85; 95% CI = 0.77 to 0.93) (Figure 2) and disease-free 
survival (HR of relapse or death = 0.81; 95% CI = 0.75 to 0.88) 
(Figure 3) compared with patients who received conventional che-
motherapy. No heterogeneity was observed among the trials for 
overall survival (I
2 = 0%), and low heterogeneity was observed for 
disease-free survival (I
2 = 37%).
A funnel plot of the primary outcome revealed slight asymmetry, 
which  may  indicate  a  small  study  effect  (ie,  publication  bias) 
Figure 4. Forest plot of hazard ratios (HRs) comparing disease-free sur-
vival  for  estrogen  receptor–positive  and  estrogen  receptor–negative 
patients who received dose-dense chemotherapy vs those who received 
conventional chemotherapy in the conserved dose-dense chemotherapy 






Figure  5.  Funnel  plot  of  overall  survival  in  all  dose-dense  chemo-
therapy trials for the visual detection of systematic publication bias 





(Figure  5).  However,  neither  the  Egger  linear  regression  test   
(P = .066) nor the Begg–Mazumdar rank correlation test (P = .14) 
showed  a  statistically  significant  association  between  the  study   
effects and the study size.
Meta-analysis of Adverse Events
In the three conserved dose-dense chemotherapy trials, there was 
no difference in the number of grade 3 or 4 adverse events between 1852   Articles | JNCI  Vol. 102, Issue 24  |  December 15, 2010
Figure  6.  Forest  plots  of  relative  risks  (RRs)  of  adverse  events  for 
patients who received dose-dense chemotherapy vs those who received 








the dose-dense and conventional chemotherapy arms (RR = 1.13; 
95% CI = 0.91 to 1.39, I
2 = 0%) (Figure 6, A). Delivery of dose-
dense chemotherapy requires the use of growth factor support, 
which may prevent grade 3 and 4 neutropenia. We therefore per-
formed an analysis that excluded bone marrow–related toxicity. 
The number of grade 3 or 4 nonhematological adverse events was 
higher in the dose-dense chemotherapy arm than in the conven-
tional chemotherapy arm (RR = 1.32; 95% CI = 1.04 to 1.66, I
2 = 
0%) (Figure 6, B). We obtained nonconclusive results regarding 
adverse  events  in  the  modified  dose-dense  chemotherapy  trials 
because  of  high  heterogeneity  (I
2  =  95.8%).  Thus,  we  used  a 
random-effect model, which showed  non-statistically significant 
higher  toxicity  in  the  dose-dense  chemotherapy  arm  compared 
with the conventional chemotherapy arm (RR = 1.36; 95% CI = 
0.87 to 2.13; P = .18).
Discussion
This systematic review and meta-analysis shows that dose-dense 
chemotherapy for the treatment of women with high-risk breast 
cancer improves both disease-free and overall survival compared 
with conventional chemotherapy. The dose-dense chemotherapy 
approach resulted in better overall survival and better disease-free 
survival  in  trials  that  evaluated  similar  doses  of  agents  in  both 
treatment arms but with a condensed schedule in one arm as well 
as in trials that compared a condensed schedule with standard one 
but used different agents or doses in the two arms. The results for 
all trials combined were statistically significant, with no statistical 
heterogeneity among the trials.
The other important finding of this systematic review is the 
paucity  of  randomized  controlled  trials  with  an  adequate  study 
design, that is, trials that evaluate the same agents and doses in the 
conventional arm as in the investigational arm. Most of the trials 
included in the meta-analysis did not preserve this last characteristic, 
which is why we classified the trials according to their design.
Two recent trials have addressed the dose-dense chemotherapy 
approach.  The  recently  published  Canadian  MA21  trial  (23), 
which  included  three  treatment  arms  that  were  anthracycline 
based, may provide key answers about the efficacy of the dose-
dense approach with and without the use of taxane therapy. The 
PREPARE trial (24), which evaluated the effect of preoperative 
dose-dense and dose-intensified chemotherapy with anthracycline 
and  taxane  with  or  without  darbepoetin  alfa  in  breast  cancer 
patients, was not included in the meta-analysis due to lack of out-
come data.
Our meta-analysis of the efficacy of dose-dense chemotherapy 
according  to  hormone  receptor  status  revealed  that  hormone 
receptor–positive patients did not benefit from dose-dense chemo-
therapy. This result was based on data from the conserved dose-
dense  chemotherapy  trials;  data  from  the  modified  dose-dense 
chemotherapy trials were not available. Nevertheless, data from 
the MA21 trial further support this finding. In the MA21 trial, 
relapse-free survival did not differ between the treatment arms in 
estrogen receptor–positive patients. Restricting the use of dose-
dense chemotherapy to hormone receptor–negative patients may 
be justified, both in terms of the costs and the potential adverse 
events (25).
We also found that there was no increase in overall treatment-
related  adverse  events  associated  with  the  dose-dense  approach. 
Because a dose-dense chemotherapy schedule requires granulocyte 
colony-stimulating  factor  support,  we  performed  an  analysis  of 
adverse events that excluded bone marrow–related events. In the jnci.oxfordjournals.org    JNCI | Articles 1853
conserved dose-dense chemotherapy trials, the number of nonhema-
tological adverse events for the dose-dense chemotherapy arms was 
higher compared with that in the conventional chemotherapy arm. 
However, because of high heterogeneity among the modified dose-
dense chemotherapy trials, the increase in adverse events for dose-
dense vs conventional chemotherapy was not statistically significant.
The  dose-dense  chemotherapy  approach  uses  prophylactic 
growth factor support to facilitate the safe delivery of dose-dense 
chemotherapy (26,27). The economic burden of this issue, as well 
as possible unrecognized growth factor–related toxicities, such as 
pulmonary toxicity, should be considered (28).
Several limitations of this analysis must be acknowledged. First, 
only three randomized controlled trials used the same agents and 
doses in the conventional chemotherapy arm as in the investiga-
tional (ie, dose-dense chemotherapy) arm. The fact that most of 
the included trials did not evaluate the same agents and dose in 
both arms resulted in major statistical heterogeneity among the 
trials. Second, the slight asymmetry of the funnel plot of the pri-
mary outcome suggests small study effects. Although results of the 
Egger and Begg–Mazumdar tests did not support the possibility of 
publication bias, the small number of included trials makes it diffi-
cult to distinguish a chance finding from true asymmetry. Also, the 
small number of included trials makes the outcomes more likely to 
have been influenced by a potential publication bias. We attempted 
to avoid such bias by searching for and including in our meta-
analysis conference proceedings, databases of ongoing trials, and 
unpublished data.
Studies are needed to better define the patient population that 
will benefit the most from dose-dense chemotherapy. The concept 
of metronomic chemotherapy as evaluated, for example, by the 
Southwest Oncology Group (29) is a variation of the dose-dense 
strategy whereby chemotherapy is administered as relatively low 
and minimally toxic doses at frequent and regular intervals (30). 
Assessing the efficacy and feasibility of this milder chemothera-
peutic approach might identify ways to integrate biological perfor-
mance  with  the  best  treatment.  This  analysis  indicates  that 
dose-dense  chemotherapy  has  a  clear  benefit  for  patients  with 
hormone  receptor–negative  breast  cancer.  The  lack  of  obvious 
benefit in patients with hormone receptor–positive breast cancer 
shown by this analysis indicates the need for further prospective 
randomized trials of the classical conserved design in this patient 
population.
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